ACRS supply chain intelligence for Aclaris Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Aclaris Therapeutics, Inc. (ACRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOSION | BIOSION | 92% | In November 2024, we entered into an exclusive license agreement (the “Biosion Agreement”) with Biosion, pursuant to which we received exclusive rights to develop, manufacture and commercialize bosak… |
| CTTQ | CTTQ | 92% | In connection with the Biosion Agreement, we also entered into a collaboration agreement (the "CTTQ Agreement") with Biosion and CTTQ, a licensee of bosakitug in Greater China. |
| OCM-IP-HEALTHCARE-PORTFOLIO-LP | OCM-IP-HEALTHCARE-PORTFOLIO-LP | 92% | In exchange, OMERS acquired a portion of the royalty payable by Lilly to us for worldwide net sales of OLUMIANT for the treatment of alopecia areata from April 1, 2024 through the remainder of the ro… |
| PEDIATRIX-THERAPEUTICS-INC | PEDIATRIX-THERAPEUTICS-INC | 90% | Under the license agreement, the Company granted Pediatrix the exclusive rights to develop, manufacture and commercialize lepzacitinib in Greater China. |
| SUN-PHARMACEUTICAL-INDUSTRIES-INC | SUN-PHARMACEUTICAL-INDUSTRIES-INC | 90% | Under the license agreement, the Company granted Sun Pharma exclusive rights under certain patents that the Company exclusively licenses from a third party. |
| LLY | Eli Lilly and Company | 80% | Under the terms of the royalty purchase agreement, we sold to OMERS a portion of the future royalty payments and the remaining anniversary milestone payments associated with our existing license to E… |
| LLY | Eli Lilly and Company | 80% | Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: Under the terms of the royalty purchase agreement, we sold to OMERS a portion of the future royalty payments and the r… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary… |
| SLGL | Sol-Gel Technologies Ltd. | 72% | Reciprocal relationship from SLGL graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL g… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: able product candidate, and there… |
| CONFLUENCE | CONFLUENCE | 70% | A portion of the consideration received from Pediatrix is payable to the former Confluence equity holders as described below under the caption “— Agreement and Plan of Merger - Confluence.” |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LLY | Eli Lilly and Company | 92% | Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: OMERS acquired a portion of the royalty payable by Lilly to us for worldwide net sales of OLUMIANT for the treatment o… |
| LLY | Eli Lilly and Company | 92% | OMERS acquired a portion of the royalty payable by Lilly to us for worldwide net sales of OLUMIANT for the treatment of alopecia areata from April 1, 2024 through the remainder of the royalty term un… |
| PEDIATRIX-THERAPEUTICS-INC | PEDIATRIX-THERAPEUTICS-INC | 92% | Pediatrix has paid the Company an upfront payment, and has agreed to pay the Company development, regulatory and commercial milestone payments upon the achievement of specified milestones set forth i… |
| SUN-PHARMACEUTICAL-INDUSTRIES-INC | SUN-PHARMACEUTICAL-INDUSTRIES-INC | 92% | Under the license agreement, Sun Pharma has paid the Company upfront, regulatory and commercial milestone payments, and has agreed to pay the Company other regulatory and commercial milestone payment… |
| OMERS | OMERS | 80% | In exchange, OMERS acquired a portion of the royalty payable by Lilly to us for worldwide net sales of OLUMIANT for the treatment of alopecia areata |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary… |
| ORANY | ORANY | 72% | are and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from ORAN… |
| SLGL | Sol-Gel Technologies Ltd. | 72% | Reciprocal relationship from SLGL graph: in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: able product candidate, and there is a risk that we may never do so. If we are unable to identify successful product… |
| SNYNF | Sanofi | 72% | able product candidate, and there is a risk that we may never do so. If we are unable to identify successful product candidates for preclinical and clinical development and regulatory approval in a t… |
| CONFLUENCE-LIFE-SCIENCES-INC | CONFLUENCE-LIFE-SCIENCES-INC | 62% | d preclinical testing of the Company’s product candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully develop its p… |
| NASDAQ-STOCK-MARKET-LLC | NASDAQ-STOCK-MARKET-LLC | 62% | and the Nasdaq Stock Market LLC, requires public companies to implement specified corporate governance practices that could increase our compliance costs. We believe our existing cash, cash equival… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ACRS-DEBT-7486 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| ACRS-DEBT-7485 | Warrants outstanding: 0.956 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| ACRS-DEBT | Debt stack $10.7M | 90% | Market cache reports total debt of $10.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ACRS-OWNER-BML-CAPITAL-MANAGEMENT-LLC | BML Capital Management, LLC | 90% | 13F overlay lists BML Capital Management, LLC as top holder; 139 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GRFS | Grifols, S.A. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| TEVJF | Teva Pharmaceutical Industries Limited | 100.00 | 2 | |
| GIKLY | Grifols, S.A. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer'] |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 1 | ['customer', 'supplier'] |
| GIFOF | Grifols, S.A. | 100.00 | 2 | |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| BFRIW | Biofrontera Inc. | 50.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 50.00 | 2 | |
| AMXOF | AMERICA MOVIL SAB DE CV/ | 50.00 | 2 | |
| BLRX | BioLineRx Ltd. | 50.00 | 2 |